2006, Number 1
<< Back Next >>
Rev Mex Mastol 2006; 1 (1)
Long survival in a patient with metastatic mucinous carcinoma of mamma
Ramírez UMT, Alvarado MA, Fuentes AA, Vela CTA, Robles VC
Language: Spanish
References: 8
Page: 39-42
PDF size: 181.61 Kb.
ABSTRACT
We present the case of a 51 years old woman with metastatic breast cancer, histologically a mucinous carcinoma with an evolution of 20th years, who was Treated with gosereline
® as monotherapy since 13 years ago, alive with estable metastatic pulmonary disease.
REFERENCES
Rosen P. Rosen’s breast pathology. 2nd edition. Williams & Wilkins, 2001.
Toikkanen S, Kujari H. Pure and mixed mucinous carcinoma of the breast: a clinicopathologic analysis of 61 cases with long-term follow-up. Hum Pathol 1989; 20: 758-764.
Rasmussen Bb, Rose C, Christensen I. Prognostic factors in primary mucinous breast carcinoma. Am J Clin Pathol 1987; 87: 155-160.
Blamy RW et al. Goserelina depot in the treatment of preme-nopausal advanced cancer. European Journal of Cancer 1992; 28: 810-814.
Jonat W., Kaufmann M, Blamey RW et al. A randomized study to compare the effect of a luteinizing hormone (LHRH) analogue gosereline with or without tamoxifen in pre and perimenopausal patients with advanced breast cancer tumor; 1994; 80: 28 – 32.
Kaufmann M. The depot GnRM analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer a 5 year experience and further endocrine therapies. Oncolokie 14: 22-30, 191.
Dixon AR. Goserelin Zoladex in premenopausal advanced breast cancer. Br J Cancer 1990; 62; 868-870.
Buzzoni R. Bigazol. Therapy in premenopausal advanced breast cancer. A multicentric study by the ITMO group Italian trials in medical Oncology. Br J Cancer 1995; 71: 1111-1114.
Full text